News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Study Presented At SAGES 2014 Shows Anterior Fundoplication With Medigus (MDGS.TA)' MUSE™ System Can Reduce GERD Patients' Use Of Ppis


4/7/2014 8:49:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OMER, Israel, April 7, 2014 (GLOBE NEWSWIRE) -- Medigus Ltd. (TASE: MDGS), a medical device company developing and commercializing minimally invasive endosurgical tools and procedures, announced two studies on the MUSE(TM) (formerly the SRS(TM)) system were highlighted as oral presentations during the prestigious 2014 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Emerging Technology Session in Salt Lake City, Utah. The first study confirmed MUSE as a trans-oral, effective treatment option for Gastroesophageal Reflux Disease (GERD), reporting that in a study of 69 subjects, 85% of patients reduced GERD medication use by >= 50% with 65% of subjects eliminating GERD medication entirely after 6 months. The study also found that 73% of subjects improved quality of life scores by >= 50%. The second study on a swine model explored the feasibility of adding MUSE to address the potential for GERD after performing a per-oral esophageal myotomy (POEM) procedure for achalasia.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
Medigus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES